Back To: Home : Featured Technology : Functional Genomic Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Quanticel, Celgene announce strategic collaboration
December 2011
SHARING OPTIONS:

SAN FRANCISCO—Quanticel Pharmaceuticals Inc. and Celgene, along with Versant Ventures, have announced the beginning of an exclusive, strategic collaboration for the discovery and development of first-in-class cancer drugs. Per the agreement, Celgene will pay Quanticel $45 million during the initial three-and-a-half-year alliance term, with the option of extending the collaboration in exchange for additional funding. In addition, Celgene will take an equity stake in Quanticel and will retain an exclusive option to acquire the company. Quanticel's responsibilities will consist of using its platform to conduct single-cell genomic analysis of patient tumor samples and to identify predictive biomarkers for Celgene investigational drugs. Quanticel will also use its platform to perform independent drug discovery for the generation of its own drug candidates, which Celgene will have the ability to access through its acquisition option. The partnership will make use of a unique funding structure between Quanticel, Celgene and Versant Ventures.


Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.